Connor, Clark & Lunn Investment Management (CC&L)’s Pacira BioSciences PCRX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-135,612	Closed	-$3.49M	–	1725
2025 Q3	$3.49M	Sell	135,612 -79,078	-37%	-$1.94M	0.01%	687
2025 Q2	$5.13M	Buy	214,690 +43,313	+25%	+$1.09M	0.02%	564
2025 Q1	$4.26M	Buy	171,377 +127,240	+288%	+$3.05M	0.02%	537
2024 Q4	$832K	Sell	44,137 -36,396	-45%	-$639K	﹤0.01%	997
2024 Q3	$1.21M	Buy	+80,533	New	+$1.38M	0.01%	822
2023 Q3	–	Sell	-27,691	Closed	-$1.11M	–	1494
2023 Q2	$1.11M	Sell	27,691 -14,232	-34%	-$588K	0.01%	767
2023 Q1	$1.71M	Buy	41,923 +25,930	+162%	+$1.03M	0.01%	586
2022 Q4	$617K	Buy	+15,993	New	+$778K	﹤0.01%	819
2022 Q2	–	Sell	-6,574	Closed	-$502K	–	1164
2022 Q1	$502K	Sell	6,574 -1,911	-23%	-$127K	﹤0.01%	785
2021 Q4	$511K	Buy	+8,485	New	+$468K	﹤0.01%	795
2014 Q2	–	Sell	-5,400	Closed	-$417K	–	610
2014 Q1	$417K	Buy	+5,400	New	+$367K	﹤0.01%	512

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s PCRX Position: Q4 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Pacira BioSciences (PCRX) in Q4 2025, closing a stake of 135,612 shares — an estimated $3.49M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PCRX in Q1 2014 and held it in 11 quarters. The position peaked at $5.13M in Q2 2025. 260 funds tracked by Wall St. Rank hold PCRX as of Q4 2025.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Pacira BioSciences position as of Q4 2025 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 135,612 Pacira BioSciences shares in Q4 2025, an estimated $3.49M.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Pacira BioSciences in Q1 2014 and held it in 11 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Pacira BioSciences position peaked at $5.13M in Q2 2025.
260 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2025, filed 10 Feb 2026.